Genmab initiates Phase I/II colorectal cancer study
The study will include a maximum of 97 patients who have failed standard chemotherapy and progressed during or within three months of stopping cetuximab-based therapy. This open label
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.
Under the terms of the agreement, which includes two one-year extension options, Impulse Monitoring (IMI) will provide University of Virginia Health System (UVAHS) with comprehensive intraoperative neuromonitoring (IONM)